Top Markets
#1 GEKKO GEKKO +53.94%
#2 Helium Helium +47.23%
#3 Pons Pons +25.55%
#4 Main Street Yield Main Street Yield +17.48%
#5 龙虾 (Lobster) 龙虾 (Lobster) +15.91%
#6 Collect on Fanable Collect on Fanable +14.24%
#7 o1.exchange o1.exchange +14.04%
#8 Ontology Gas Ontology Gas +11.63%
#9 Nockchain Nockchain +11.47%
#10 OpenGradient OpenGradient +10.61%
Coin of the day
GEKKO GEKKO
Cài đặt
Ngôn ngữ
TIếNG VIệT
Tiền tệ
USD
Chủ đề
Corvus Pharmaceuticals, Inc. Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CRVS
Xếp hạng trong cổ phiếu #8729
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Giá cổ phiếu
$14.07
Đồng bộ lần cuối: 2026-08-28
Vốn hóa thị trường
$1.18B
Thay đổi (1 ngày)
-4.41%
Thay đổi (1 năm)
145.13%
Quốc gia
US
Giao dịch Corvus Pharmaceuticals, Inc. (CRVS)

Danh mục

Healthcare
Lịch sử giá cổ phiếu của Corvus Pharmaceuticals, Inc. (CRVS)
Giá đóng cửa cao nhất: $14.55 vào 2026-08-01

Giá đóng cửa thấp nhất: $14.35 vào 2016-03-01
Lịch sử giá cổ phiếu của Corvus Pharmaceuticals, Inc. từ 2016 đến 2026
Hiệu suất giá cổ phiếu hàng năm
Năm Hiệu suất
2026 (TTM) 52.04%
2025 20.69%
2024 304.94%
2023 86.02%
2022 -68.55%
2021 -28.60%
2020 -6.17%
2019 -13.67%
2018 -53.58%
2017 -32.68%
2016 0.00%
Giá cổ phiếu của các công ty hoặc đối thủ tương tự
Công ty Giá cổ phiếu Thay đổi 1năm% Quốc gia
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $542.09 38.63%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.03K 44.13%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.53 -12.70%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $138.18 473.58%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $759.27 7.20%
CH